<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407822</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Challenges of Treating a <i>Helicobacter pylori</i> Infection following the COVID-19 Pandemic in Croatia: A Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5762</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195762</ELocationID><Abstract><AbstractText><b>Background:</b><i>Helicobacter pylori</i> (<i>H. pylori</i>) is a prevalent bacterial pathogen implicated in different stomach and duodenal diseases, including chronic gastritis, gastric and duodenal ulcer, and stomach cancer. The COVID-19 pandemic has significantly influenced antibiotic prescription practices, potentially exacerbating antibiotic resistance in <i>H. pylori</i>. <b>Objective:</b> This study aims to investigate antibiotic prescription during the COVID-19 pandemic in Croatia and its possible impact on <i>H. pylori</i> antibiotic resistance, with a focus on Croatia. <b>Methods:</b> An extensive literature search was conducted to identify relevant studies from March 2020 to June 2024. The search strategy included terms related to COVID-19, antibiotic prescription, and Croatia. Studies were selected based on predefined eligibility criteria, focusing on observational research addressing antibiotic use during the pandemic. <b>Results:</b> The COVID-19 pandemic has led to significant fluctuations in community antibiotic consumption within the European Union/European Economic Area. In Croatia, antibiotic use in 2022 surpassed 2019 levels, driven by increased consumption of macrolides and other antibiotics. This surge, influenced by early pandemic treatment claims and penicillin shortages, contributed to rising antibiotic resistance in <i>H. pylori</i>. Resistance rates to clarithromycin and levofloxacin were notably high, driven by mutations in the 23S rRNA, gyrA, and gyrB genes. <b>Discussion:</b> The increased antibiotic use during the COVID-19 pandemic has highly likely complicated <i>H. pylori</i> eradication efforts, highlighting the necessity of judicious antibiotic use and robust antimicrobial stewardship. The pandemic underscored the need for new therapeutic strategies, optimized eradication regimens, and advanced diagnostic methods to manage bacterial infections effectively. <b>Conclusions:</b> The COVID-19 pandemic has significantly affected antibiotic use and resistance patterns, posing new challenges for <i>H. pylori</i> eradication. Addressing these challenges requires a multifaceted approach, including the development of new drugs and advanced diagnostics, coupled with sustained efforts in antimicrobial stewardship to combat emerging resistance threats.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jukic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4669-666X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospital Split, Spinciceva 1, 21000 Split, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Studies, University of Split, 21000 Split, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vukovic</LastName><ForeName>Jonatan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7878-7988</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospital Split, Spinciceva 1, 21000 Split, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">H. pylori</Keyword><Keyword MajorTopicYN="N">antibiotic consumption</Keyword><Keyword MajorTopicYN="N">antibiotic resistance</Keyword><Keyword MajorTopicYN="N">antimicrobial stewardship</Keyword><Keyword MajorTopicYN="N">eradication therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407822</ArticleId><ArticleId IdType="pmc">PMC11477188</ArticleId><ArticleId IdType="doi">10.3390/jcm13195762</ArticleId><ArticleId IdType="pii">jcm13195762</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baj J., Forma A., Sitarz M., Portincasa P., Garruti G., Krasowska D., Maciejewski R. Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2020;10:27. doi: 10.3390/cells10010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010027</ArticleId><ArticleId IdType="pmc">PMC7824444</ArticleId><ArticleId IdType="pubmed">33375694</ArticleId></ArticleIdList></Reference><Reference><Citation>Öztekin M., Yılmaz B., Ağagündüz D., Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases. 2021;9:66. doi: 10.3390/diseases9040066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases9040066</ArticleId><ArticleId IdType="pmc">PMC8544542</ArticleId><ArticleId IdType="pubmed">34698140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mommersteeg M.C., Yu J., Peppelenbosch M.P., Fuhler G.M. Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms. Biochim. Biophys. Acta Rev. Cancer. 2018;1869:42–52. doi: 10.1016/j.bbcan.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2017.11.003</ArticleId><ArticleId IdType="pubmed">29154808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.C., Chiang T.H., Chou C.K., Tu Y.K., Liao W.C., Wu M.S., Graham D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150:1113–1124.e5. doi: 10.1053/j.gastro.2016.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.01.028</ArticleId><ArticleId IdType="pubmed">26836587</ArticleId></ArticleIdList></Reference><Reference><Citation>Megraud F., Bruyndonckx R., Coenen S., Wittkop L., Huang T.D., Hoebeke M., Bénéjat L., Lehours P., Goossens H., Glupczynski Y., et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815–1822. doi: 10.1136/gutjnl-2021-324032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324032</ArticleId><ArticleId IdType="pubmed">33837118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tshibangu-Kabamba E., Yamaoka Y. Helicobacter pylori infection and antibiotic resistance—From biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 2021;18:613–629. doi: 10.1038/s41575-021-00449-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00449-x</ArticleId><ArticleId IdType="pubmed">34002081</ArticleId></ArticleIdList></Reference><Reference><Citation>Šamanic I., Dadić B., Sanader Maršić Ž., Dželalija M., Maravić A., Kalinić H., Vrebalov Cindro P., Šundov Ž., Tonkić M., Tonkić A., et al. Molecular Characterization and Mutational Analysis of Clarithromycin- and Levofloxacin-Resistance Genes in Helicobacter pylori from Gastric Biopsies in Southern Croatia. Int. J. Mol. Sci. 2023;24:14560. doi: 10.3390/ijms241914560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241914560</ArticleId><ArticleId IdType="pmc">PMC10572715</ArticleId><ArticleId IdType="pubmed">37834008</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Coronavirus Disease (COVID-19) Pandemic.  [(accessed on 1 August 2024)].  Available online:  https://www.who.int/europe/emergencies/situations/covid-19.</Citation></Reference><Reference><Citation>Mladenova I. Epidemiology of Helicobacter pylori Resistance to Antibiotics (A Narrative Review) Antibiotics. 2023;12:1184. doi: 10.3390/antibiotics12071184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12071184</ArticleId><ArticleId IdType="pmc">PMC10376713</ArticleId><ArticleId IdType="pubmed">37508280</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyanova L., Hadzhiyski P., Gergova R., Markovska R. Evolution of Helicobacter pylori Resistance to Antibiotics: A Topic of Increasing Concern. Antibiotics. 2023;12:332. doi: 10.3390/antibiotics12020332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12020332</ArticleId><ArticleId IdType="pmc">PMC9952372</ArticleId><ArticleId IdType="pubmed">36830243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A., Ghazy R.M., Sherief D., Ismail A., Ellakany W.I. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: A randomized clinical trial. BMC Infect. Dis. 2023;23:36. doi: 10.1186/s12879-023-07993-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-07993-8</ArticleId><ArticleId IdType="pmc">PMC9854408</ArticleId><ArticleId IdType="pubmed">36670359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanić N., Močibob L., Vidović T., Soldo A., Begovać J. Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020. PLoS ONE. 2022;17:e0263437.  doi: 10.1371/journal.pone.0263437. Erratum in PLoS ONE
2022, 17, e0272324. https://doi.org/10.1371/journal.pone.0272324 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263437</ArticleId><ArticleId IdType="pmc">PMC8809604</ArticleId><ArticleId IdType="pubmed">35108332</ArticleId></ArticleIdList></Reference><Reference><Citation>Papst L., Luzzati R., Carević B., Tascini C., Gorišek Miksić N., Vlahović Palčevski V., Djordjevic Z.M., Simonetti O., Sozio E., Lukić M., et al. Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics. 2022;11:176. doi: 10.3390/antibiotics11020176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11020176</ArticleId><ArticleId IdType="pmc">PMC8868464</ArticleId><ArticleId IdType="pubmed">35203779</ArticleId></ArticleIdList></Reference><Reference><Citation>Šokota A., Prtorić L., Hojsak I., Trivić I., Jurić F., Lah Tomulić K., Roganović J., Nikolić H., Bosak Veršić A., Markić J., et al. Pediatric tertiary emergency care departments in Zagreb, Rijeka, and Split before and during the coronavirus disease 2019 pandemic: A Croatian national multicenter study. Croat. Med. J. 2021;62:580–589. doi: 10.3325/cmj.2021.62.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2021.62.580</ArticleId><ArticleId IdType="pmc">PMC8771230</ArticleId><ArticleId IdType="pubmed">34981690</ArticleId></ArticleIdList></Reference><Reference><Citation>Šutej I., Lepur D., Bašić K., Šimunović L., Peroš K. Changes in Medication Prescribing Due to COVID-19 in Dental Practice in Croatia-National Study. Antibiotics. 2023;12:111. doi: 10.3390/antibiotics12010111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12010111</ArticleId><ArticleId IdType="pmc">PMC9854617</ArticleId><ArticleId IdType="pubmed">36671312</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control . Surveillance of Antimicrobial Resistance in Europe 2018. ECDC; Stockholm, Sweden: 2019.</Citation></Reference><Reference><Citation>Beović B., Doušak M., Ferreira-Coimbra J., Nadrah K., Rubulotta F., Belliato M., Berger-Estilita J., Ayoade F., Rello J., Erdem H. Antibiotic use in patients with COVID-19: A ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J. Antimicrob. Chemother. 2020;75:3386–3390. doi: 10.1093/jac/dkaa326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa326</ArticleId><ArticleId IdType="pmc">PMC7454563</ArticleId><ArticleId IdType="pubmed">32766706</ArticleId></ArticleIdList></Reference><Reference><Citation>Council of the European Union  Council Recommendation on Stepping up EU Actions to Combat Antimicrobial Resistance in a One Health Approach. 2023.  [(accessed on 1 August 2024)].  Available online:  https://health.ec.europa.eu/publications/council-recommendation-stepping-eu-actions-combat-antimicrobial-resistance-one-health-approach_en.</Citation></Reference><Reference><Citation>Ventura-Gabarró C., Leung V.H., Vlahović-Palčevski V., Machowska A., Monnet D.L., Högberg L.D., ESAC-Net Study Group Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022. Eurosurveillance. 2023;28:2300604. doi: 10.2807/1560-7917.ES.2023.28.46.2300604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.46.2300604</ArticleId><ArticleId IdType="pmc">PMC10655206</ArticleId><ArticleId IdType="pubmed">37971660</ArticleId></ArticleIdList></Reference><Reference><Citation>European Surveillance of Antimicrobial Consumption Network (ESAC-Net)   Annual Epidemiological Report for 2021. ECDC; Stockholm, Sweden: 2022.  [(accessed on 1 August 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/ESAC-Net_AER_2021_final-rev.pdf.</Citation></Reference><Reference><Citation>Ghiga I., Pitchforth E., Stålsby Lundborg C., Machowska A. Family doctors’ roles and perceptions on antibiotic consumption and antibiotic resistance in Romania: A qualitative study. BMC Prim. Care. 2023;24:93. doi: 10.1186/s12875-023-02047-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-023-02047-z</ArticleId><ArticleId IdType="pmc">PMC10084585</ArticleId><ArticleId IdType="pubmed">37038124</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S., Joy M., Sherlock J., Tripathy M., van Hecke O., Gbinigie K., Williams J., Butler C., Hobbs F.R. PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship: A retrospective sentinel network cohort study. BJGP Open. 2021;5:BJGPO.2021.0087. doi: 10.3399/BJGPO.2021.0087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGPO.2021.0087</ArticleId><ArticleId IdType="pmc">PMC8596310</ArticleId><ArticleId IdType="pubmed">34312163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R., Pettoello-Mantovani M., Giardino I., Carrasco-Sanz A., Somekh E., Levy C. The Shortage of Amoxicillin: An Escalating Public Health Crisis in Pediatrics Faced by Several Western Countries. J. Pediatr. 2023;257:113321. doi: 10.1016/j.jpeds.2023.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2023.01.001</ArticleId><ArticleId IdType="pubmed">36669589</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., Gasbarrini A., Hunt R.H., Leja M., O’Morain C., et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 2022;71:1724–1762. doi: 10.1136/gutjnl-2022-327745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2022-327745</ArticleId><ArticleId IdType="pubmed">35944925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestrovic A., Perkovic N., Bozic J., Pavicic Ivelja M., Vukovic J., Kardum G., Puljiz Z., Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS ONE. 2020;15:e0244500. doi: 10.1371/journal.pone.0244500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244500</ArticleId><ArticleId IdType="pmc">PMC7773256</ArticleId><ArticleId IdType="pubmed">33378403</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic N., Mestrovic A., Bozic J., Ivelja M.P., Vukovic J., Kardum G., Sundov Z., Tonkic M., Puljiz Z., Vukojevic K., et al. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J. Pers. Med. 2021;11:534. doi: 10.3390/jpm11060534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11060534</ArticleId><ArticleId IdType="pmc">PMC8229321</ArticleId><ArticleId IdType="pubmed">34207870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonkić M., Tonkić A., Goić-Barisić I., Jukić I., Simunić M., Punda-Polić V. Primary resistance and antibiotic minimum inhibitory concentrations for Helicobacter pylori strains, in Split, Croatia. J. Chemother. 2006;18:437–439. doi: 10.1179/joc.2006.18.4.437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/joc.2006.18.4.437</ArticleId><ArticleId IdType="pubmed">17024803</ArticleId></ArticleIdList></Reference><Reference><Citation>Manesh A., Varghese G.M. CENDRIC Investigators and Collaborators. Rising antimicrobial resistance: An evolving epidemic in a pandemic. Lancet Microbe. 2021;2:e419–e420. doi: 10.1016/S2666-5247(21)00173-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00173-7</ArticleId><ArticleId IdType="pmc">PMC8248924</ArticleId><ArticleId IdType="pubmed">34230918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jukic I., Vukovic J., Rusic D., Bozic J., Bukic J., Leskur D., Seselja Perisin A., Modun D. Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study. Helicobacter. 2021;26:e12775. doi: 10.1111/hel.12775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12775</ArticleId><ArticleId IdType="pubmed">33368852</ArticleId></ArticleIdList></Reference><Reference><Citation>Jukic I., Rusic D., Vukovic J., Zivkovic P.M., Bukic J., Leskur D., Seselja Perisin A., Luksic M., Modun D. Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection. Basic Clin. Pharmacol. Toxicol. 2020;126:212–225. doi: 10.1111/bcpt.13322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13322</ArticleId><ArticleId IdType="pubmed">31520459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>